An estrogen-blocking drug reduces the risk of breast cancer

A breast cancer is one of the most significant cancers affecting women, and its causes are diverse. Researchers are continuously working to find the most effective prevention and treatment methods. According to the latest research, a new drug that inhibits the estrogen hormone could significantly reduce the risk of developing breast cancer among high-risk women.

The risk of breast cancer depends on various factors and cannot be attributed to a single lifestyle choice. The medical community emphasizes that the disease can occur in any woman, regardless of how much she takes care of her health. New research may provide new hope for high-risk women who have had limited options for prevention so far.

Risk Factors for Breast Cancer

An array of factors influences the risk of developing breast cancer, many of which are not clearly linked to external influences. The scientific community generally agrees that breast cancer is not solely dependent on lifestyle, meaning that women in the best health can also be affected. The occurrence of the disease is also associated with age, genetic factors, and hormonal changes.

Particular attention should be given to women with BRCA gene mutations, as this significantly increases the likelihood of developing breast cancer. During research, scientists aimed to identify intervention options that could help prevent the disease in high-risk groups. In the international study, researchers involved thousands of participants, including those taking the latest drug, anastrozole, and those receiving a placebo.

During the research, the health status of participants was monitored over five years, with the goal of understanding how effective anastrozole is in preventing breast cancer. The results indicated that taking the drug significantly reduces the likelihood of the disease developing in high-risk women.

The Effect of Anastrozole on Breast Cancer Prevention

Anastrozole is an aromatase inhibitor that works by lowering estrogen hormone levels. Reducing estrogen levels may be particularly important in preventing the development of breast cancer, as the disease often presents in a hormone-sensitive form. The drug is currently used to treat advanced breast cancer, but the latest research shows it may also offer significant benefits in the prevention field.

In the study, less than 3% of participants taking anastrozole developed breast cancer, while the rate among those taking the placebo exceeded 5%. This difference clearly indicates that anastrozole may be a more effective solution for preventing the disease compared to previous therapies, such as tamoxifen.

Professor Jack Cuzick, the lead researcher, emphasized that taking anastrozole not only results in fewer side effects but is also much more effective than earlier medications. This creates new opportunities for high-risk women who have had limited choices for disease prevention.

The application of anastrozole in breast cancer prevention depends not only on the drug’s effectiveness but also on how well the female population accepts new treatment options. The new research findings provide hope for the future and offer the potential for breast cancer prevention to become increasingly effective.